University of California

The University of Texas System

United States of America As Represented by the Secretary of the Air Force

The General Hospital Corporation

University of Colorado

Mount Sinai Hospital Corporation

Gerry R Boss

Matthew D Brenner

Vijay Sharma

Kate Broderick

Sari Mahon

Adriano Chan

Purnendu K Dasgupta

Karen L Christman

Randall T Peterson

Anthony J Pawson

Vikhyat Bebarta

Joann Luu

Adam Kimmerly

Jingjing Jiang

Jean Wang Wassenaar

Matthew Christopher Mycroft

Robert Gerszten

William Curt Blackledge

Anjali Nath

Matt Brenner

Stephen B Jones

Jurgen S Scheele

Abhijit Guha

Sari Brenner-Mahon

Jeffrey C Chen

Calum MacRae

Friederike Von Lintig

Vikhyat S Bebarta

Stephanie Hoffman

Provided is a method, and pharmaceutical composition, to treat or prevent cyanide poisoning and/or methylmercaptan poisoning comprising administering to a subject in need an effective amount of tetrathionate by intramuscular injection or by intranasal administration. Also provided is a method for detecting the presence of tetrathionate in a sample by reacting it with cyanide and measuring the resulting thiocyanate with ferric nitrate.

Tetrathionate for cyanide and methylmercaptan poisoning

The present application provides, inter alia, a compound of Formula (I): or a pharmaceutically acceptable salt thereof, and methods of use of the compound of Formula (I) for treatment and prevention of cyanide poisoning.

Antidotes to cyanide poisoning

A composition and method for treating excess cyanide and hydrogen sulfide comprising administering a cobinamide. Further a method for determining extent of binding by an agent to an extracellular matrix.

Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity

A method and devices analyze for the presence of cyanide in samples using colorimetric analysis of samples after contacting with cobinamide or monocyanocohinapmide.

Rapid method to measure cyanide in biological samples

Methods for treating disease states in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide are provided. Methods for alleviating the symptoms of a disease state in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide in the subject are also provided. Pharmaceutical compositions comprising cobinamide and a pharmaceutically acceptable carrier are also provided.

Methods and compositions for treatment of excess nitric oxide or cyanide toxicity

Compositions comprising nitrosyl-cobinamide are provided. Also provided are methods for treating hypertension, which comprise administering therapeutically effective amounts of nitrosyl-cobinamide. Also provided are methods for producing nitrosyl-cobinamide.

Nitric oxide releasing compounds

The invention is a method for the isolation of molecules of interest using tubes in which at least a portion of the inner walls of the tube are coated with microbeads that are coated with a capture reagent to bind the molecule of interest. The microbeads may be glass or polymer beads. The invention is a method and apparatus for preparation of the tubes for use in the method of the invention. The invention is a method for determining ratios of guanine nucleotides bound to guanine-nucleotide binding proteins.

Solid phase isolation of proteins, nucleic acids and other macromolecules

The invention features methods for measuring the total amounts of G protein-bound GDP and GTP in mammalian cells and tissue. The method of the invention is advantageous over conventional methods in that the cells need not be exposed to phosphate-free growth conditions, which can adversely affect the accuracy of the GTP determination. Moreover, the method does not require exposure of the cells to radiolabelled phosphate in the growth medium. Standardized amounts of G protein-bound GDP and GTP are determined relative to non-nuclear cellular protein content or cellular DNA content, allowing comparison of results across different cell types. The method is particularly applicable to the detection of Ras protein bound GTP and GDP. The determination of Ras-bound GTP levels by the method of the invention provides a sensitive and accurate means of evaluating the role of Ras activation in cellular processes, such as cell proliferative disease, hormonal secretion, cellular differentiation, programmed cell death, cell cycle regulation, and protein trafficking. Treatment of abnormal processes can then more accurately targeted to the alteration of G protein activation.

Method of quantitating GTP and GDP bound to a G protein and uses thereof

Growing community of inventors

La Jolla, CA, United States of America

Gerry R Boss